Serum potassium level and mineralocorticoid receptor antagonist dose in a large cohort of chronic heart failure patients.

Pascal Richard David ClephasSumant P RadhoeGerard C M LinssenJorina LangerveldJacobus PlompJeroen P P SmitsMichiel J NagelsmitHans-Peter Brunner-La RoccaJasper J Brugts

Published in: ESC heart failure (2023)

In this large registry of real-world chronic HF patients, both an increase in serum potassium and hyperkalaemia were associated with a lower odds of receiving the guideline-recommended MRA dose.

Keyphrases

ejection fraction
end stage renal disease
newly diagnosed
peritoneal dialysis
prognostic factors
heart failure
contrast enhanced